Dipeptidyl Peptidase-4 Inhibition in Patients with Type 2 Diabetes Treated with Saxagliptin, Sitagliptin, or Vildagliptin

INTRODUCTION: Saxagliptin, sitagliptin, and vildagliptin are dipeptidyl peptidase-4 (DPP-4) inhibitors widely approved for use in patients with type 2 diabetes. Using a crossover design, the present study compared trough levels of DPP-4 inhibition provided by these agents in a single cohort of patie...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Tatosian, Daniel A., Guo, Ying, Schaeffer, Andrea K., Gaibu, Natalia, Popa, Serghei, Stoch, Aubrey, Langdon, Ronald B., Kauh, Eunkyung A.
Format: Artigo
Idioma:Inglês
Publicat: Springer Healthcare 2013
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3889317/
https://ncbi.nlm.nih.gov/pubmed/24163113
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-013-0045-8
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars